80 related articles for article (PubMed ID: 21059092)
21. Beneficial effects of rosiglitazone on novel cardiovascular risk factors in patients with Type 2 diabetes mellitus.
Kadoglou NP; Iliadis F; Angelopoulou N; Perrea D; Liapis CD; Alevizos M
Diabet Med; 2008 Mar; 25(3):333-40. PubMed ID: 18307460
[TBL] [Abstract][Full Text] [Related]
22. Carotid intima-media thickness in relation to macrovascular disease in patients with type 2 diabetes mellitus.
Mudríková T; Szabová E; Tkác I
Wien Klin Wochenschr; 2000 Oct; 112(20):887-91. PubMed ID: 11244615
[TBL] [Abstract][Full Text] [Related]
23. Insulin sensitivity as a risk factor for common carotid intima media thickness (IMT): its relation to atherosclerosis.
Deo SS; Mahadik SR; Chogle AR; Soneji SL; Lulla CP
Clin Exp Hypertens; 2007 Oct; 29(7):445-55. PubMed ID: 17994354
[TBL] [Abstract][Full Text] [Related]
24. Acarbose slows progression of intima-media thickness of the carotid arteries in subjects with impaired glucose tolerance.
Hanefeld M; Chiasson JL; Koehler C; Henkel E; Schaper F; Temelkova-Kurktschiev T
Stroke; 2004 May; 35(5):1073-8. PubMed ID: 15073402
[TBL] [Abstract][Full Text] [Related]
25. Noninvasive measurement of carotid extra-media thickness: associations with cardiovascular risk factors and intima-media thickness.
Skilton MR; Sérusclat A; Sethu AH; Brun S; Bernard S; Balkau B; Moulin P; Bonnet F
JACC Cardiovasc Imaging; 2009 Feb; 2(2):176-82. PubMed ID: 19356553
[TBL] [Abstract][Full Text] [Related]
26. Inflammatory markers, insulin resistance and carotid intima-media thickness in North-Indian type 2 diabetic subjects.
Ahmad J; Ahmned F; Siddiqui MA; Khan AR; Katyal P; Hameed B; Ahmad I
J Assoc Physicians India; 2007 Oct; 55():693-9. PubMed ID: 18173021
[TBL] [Abstract][Full Text] [Related]
27. Intima-media thickness and carotid resistive index: progression over 6 years and predictive value for cardiovascular events.
Uthoff H; Staub D; Meyerhans A; Hochuli M; Bundi B; Schmid HP; Frauchiger B
Ultraschall Med; 2008 Dec; 29(6):604-10. PubMed ID: 18528807
[TBL] [Abstract][Full Text] [Related]
28. Effect of rosiglitazone on progression of coronary atherosclerosis in patients with type 2 diabetes mellitus and coronary artery disease: the assessment on the prevention of progression by rosiglitazone on atherosclerosis in diabetes patients with cardiovascular history trial.
Gerstein HC; Ratner RE; Cannon CP; Serruys PW; García-García HM; van Es GA; Kolatkar NS; Kravitz BG; Miller DM; Huang C; Fitzgerald PJ; Nesto RW;
Circulation; 2010 Mar; 121(10):1176-87. PubMed ID: 20194881
[TBL] [Abstract][Full Text] [Related]
29. Effect of antihypertensive therapy on progression of carotid intima-media thickness in patients with type 2 diabetes mellitus.
Zheng L; Hodis HN; Buchanan TA; Li Y; Mack WJ
Am J Cardiol; 2007 Apr; 99(7):956-60. PubMed ID: 17398191
[TBL] [Abstract][Full Text] [Related]
30. Peroxisome proliferator-activated receptor gamma agonists for the Prevention of Adverse events following percutaneous coronary Revascularization--results of the PPAR study.
Bhatt DL; Chew DP; Grines C; Mukherjee D; Leesar M; Gilchrist IC; Corbelli JC; Blankenship JC; Eres A; Steinhubl S; Tan WA; Resar JR; AlMahameed A; Abdel-Latif A; Tang WH; Brennan D; McErlean E; Hazen SL; Topol EJ
Am Heart J; 2007 Jul; 154(1):137-43. PubMed ID: 17584566
[TBL] [Abstract][Full Text] [Related]
31. Serum 25-hydroxyvitamin D3 concentrations and carotid artery intima-media thickness among type 2 diabetic patients.
Targher G; Bertolini L; Padovani R; Zenari L; Scala L; Cigolini M; Arcaro G
Clin Endocrinol (Oxf); 2006 Nov; 65(5):593-7. PubMed ID: 17054459
[TBL] [Abstract][Full Text] [Related]
32. Comparison of the effects of doxazosin and atenolol on target organ damage in adults with type 2 diabetes mellitus and hypertension in the CARDHIAC study: a 9-month, prospective, randomized, open-label, blinded-evaluation trial.
Barrios V; Escobar C; Tomás JP; Calderon A; Echarri R
Clin Ther; 2008 Jan; 30(1):98-107. PubMed ID: 18343246
[TBL] [Abstract][Full Text] [Related]
33. Reassessing the cardiovascular risks and benefits of thiazolidinediones.
Zinn A; Felson S; Fisher E; Schwartzbard A
Clin Cardiol; 2008 Sep; 31(9):397-403. PubMed ID: 18781598
[TBL] [Abstract][Full Text] [Related]
34. Effect of long-term treatment with rosiglitazone on arterial elasticity and metabolic parameters in patients with Type 2 diabetes mellitus: a 2-year follow-up study.
Shargorodsky M; Michaelova K; Boaz M; Gavish D; Zimlichman R
Diabet Med; 2007 Nov; 24(11):1254-60. PubMed ID: 17725634
[TBL] [Abstract][Full Text] [Related]
35. Are your arteries older than your age?
Labropoulos N; Leon LR; Brewster LP; Pryor L; Tiongson J; Kang SS; Mansour MA; Kalman P
Eur J Vasc Endovasc Surg; 2005 Dec; 30(6):588-96. PubMed ID: 16061404
[TBL] [Abstract][Full Text] [Related]
36. Effect of peroxisome proliferator-activated receptor gamma agonist treatment on subclinical atherosclerosis in patients with insulin-requiring type 2 diabetes.
Hodis HN; Mack WJ; Zheng L; Li Y; Torres M; Sevilla D; Stewart Y; Hollen B; Garcia K; Alaupovic P; Buchanan TA
Diabetes Care; 2006 Jul; 29(7):1545-53. PubMed ID: 16801577
[TBL] [Abstract][Full Text] [Related]
37. Effects of active and passive smoking on the development of cardiovascular disease as assessed by a carotid intima-media thickness examination in patients with type 2 diabetes mellitus.
Jiang F; Wang J; Zhang R; Chen M; Peng D; Sun X; Yan J; Luo Y; Tang S; Hu C; Jia W
Clin Exp Pharmacol Physiol; 2015 May; 42(5):444-50. PubMed ID: 25708055
[TBL] [Abstract][Full Text] [Related]
38. Long-term effects of pioglitazone on carotid atherosclerosis in Japanese patients with type 2 diabetes without a recent history of macrovascular morbidity.
Yamasaki Y; Katakami N; Furukado S; Kitagawa K; Nagatsuka K; Kashiwagi A; Daida H; Kawamori R; Kaku K
J Atheroscler Thromb; 2010 Nov; 17(11):1132-40. PubMed ID: 20686324
[TBL] [Abstract][Full Text] [Related]
39. Soluble CD40 ligand, plasminogen activator inhibitor-1 and thrombin-activatable fibrinolysis inhibitor-1-antigen in normotensive type 2 diabetic subjects without diabetic complications. Effects of metformin and rosiglitazone.
Yener S; Comlekci A; Akinci B; Demir T; Yuksel F; Ozcan MA; Bayraktar F; Yesil S
Med Princ Pract; 2009; 18(4):266-71. PubMed ID: 19494532
[TBL] [Abstract][Full Text] [Related]
40. Atherosclerosis is associated with plasminogen activator inhibitor type-1 in chronic haemodialysis patients.
Peng Y; Liu H; Liu F; Ouyang L; Cheng M; Gao L; Pan F; Liu Y; Chen X; Li J
Nephrology (Carlton); 2008 Oct; 13(7):579-86. PubMed ID: 19161364
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
